PharmacoEconomics

Volume 32, issue 6, June 2014

8 articles in this issue

Modelling Technique, Structural Assumptions, Input Parameter Values: Which Has the Most Impact on the Results of a Cost-Effectiveness Analysis?

Authors
- Josephine Mauskopf
- Content type: Commentary
- Published: 18 April 2014
- Pages: 521 - 523
Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines

Authors
- A. T. Newall
- M. Jit
- R. Hutubessy
- Content type: Current Opinion
- Published: 03 May 2014
- Pages: 525 - 531
Methods for Adjusting for Bias Due to Crossover in Oncology Trials

Authors (first, second and last of 6)
- K. Jack Ishak
- Irina Proskorovsky
- Juan Valle
- Content type: Practical Application
- Published: 05 March 2014
- Pages: 533 - 546
When to Use Discrete Event Simulation (DES) for the Economic Evaluation of Health Technologies? A Review and Critique of the Costs and Benefits of DES

Authors
- Jonathan Karnon
- Hossein Haji Ali Afzali
- Content type: Review Article
- Published: 14 March 2014
- Pages: 547 - 558
This is part of 1 collection:
Methods of Economic Evaluation
Cost-Effectiveness Analyses in Multiple Sclerosis: A Review of Modelling Approaches

Authors (first, second and last of 5)
- Shien Guo
- Christopher Pelligra
- Anuraag Kansal
- Content type: Review Article
- Published: 19 March 2014
- Pages: 559 - 572
Cost Effectiveness of a Pharmacist-Led Information Technology Intervention for Reducing Rates of Clinically Important Errors in Medicines Management in General Practices (PINCER)

Authors (first, second and last of 10)
- Rachel A. Elliott
- Koen D. Putman
- Anthony J. Avery
- Content type: Original Research Article
- Published: 18 March 2014
- Pages: 573 - 590
Using the EuroQol EQ-5D in Swiss Cancer Patients, Which Value Set Should be Applied?

Authors (first, second and last of 5)
- Klazien Matter-Walstra
- Dirk Klingbiel
- Matthias Schwenkglenks
- Content type: Original Research Article
- Published: 27 March 2014
- Pages: 591 - 599
Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation

Authors
- Torbjørn Wisløff
- Gunhild Hagen
- Marianne Klemp
- Content type: Original Research Article
- Open Access
- Published: 09 April 2014
- Pages: 601 - 612

Volume 32, issue 6, June 2014

Modelling Technique, Structural Assumptions, Input Parameter Values: Which Has the Most Impact on the Results of a Cost-Effectiveness Analysis?

Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines

Methods for Adjusting for Bias Due to Crossover in Oncology Trials

When to Use Discrete Event Simulation (DES) for the Economic Evaluation of Health Technologies? A Review and Critique of the Costs and Benefits of DES

Cost-Effectiveness Analyses in Multiple Sclerosis: A Review of Modelling Approaches

Cost Effectiveness of a Pharmacist-Led Information Technology Intervention for Reducing Rates of Clinically Important Errors in Medicines Management in General Practices (PINCER)

Using the EuroQol EQ-5D in Swiss Cancer Patients, Which Value Set Should be Applied?

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation

For authors

Explore

Volume 32, issue 6, June 2014

Authors

Authors

Authors (first, second and last of 6)

Authors

Authors (first, second and last of 5)

Authors (first, second and last of 10)

Authors (first, second and last of 5)

Authors

For authors

Explore